Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Cavenaugh, James S ^a,b,c,g   Awi, Dorka ^a,d,g   Mendy, Maimuna ^a,e,g   Hill, Adrian V S ^b,f   Whittle, Hilton ^a   McConkey, Samuel J ^a,b,g  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^d UNIVERSITY OF PORT HARCOURT   (Nigeria)

^e INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD3 ANTIGEN; DNA VACCINE; GAMMA INTERFERON; LAMIVUDINE; MODIFIED VACCINIA VIRUS ANKARA VACCINE; PLASMID DNA; UNCLASSIFIED DRUG; VACCINIA VACCINE; HEPATITIS B(E) ANTIGEN; MEMBRANE ANTIGEN; VIRUS PROTEIN;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; FEVER; GAMBIA; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; INFECTION CONTROL; INJECTION SITE ERYTHEMA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALARIA; MALE; PAIN; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SKIN SCAR; VIREMIA; VIRUS IMMUNITY; VIRUS LOAD; BIOSYNTHESIS; CELLULAR IMMUNITY; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENETICS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; SAFETY; SEROLOGY; STATISTICS; VACCINATION; VACCINIA VIRUS;

HEPATITIS B VIRUS; VACCINIA VIRUS ANKARA;

ADOLESCENT; ADULT; ANTIGENS, SURFACE; CHRONIC DISEASE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNITY, CELLULAR; INTERFERON-GAMMA; LAMIVUDINE; MALE; MEDICATION ADHERENCE; SAFETY; SEROLOGIC TESTS; VACCINATION; VACCINES, DNA; VACCINIA VIRUS; VIRAL LOAD; VIRAL PROTEINS; YOUNG ADULT;

EID: 79951866610     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014626     Document Type: Article

References (78)

1. Chisari FV, (2000) Viruses, Immunity, and Cancer: Lessons from Hepatitis B. American Journal of Pathology 156: 1117-1132.
2. Hilleman MR, (2003) Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. Vaccine 21: 4626-4649.
3. Jung M-C, Pape GR, (2002) Immunology of hepatitis B infection. The Lancet Infectious Diseases 2: 43-50.
4. Lee WM, (1997) Hepatitis B Virus Infection. New England Journal of Medicine 337: 1733-1745.
5. Nassal M, (1999) Hepatitis B Virus Replication: Novel Roles for Virus-Host Interactions. Intervirology 42: 100-116.
6. Pan CQ, Zhang JX, (2005) Natural History and Clinical Consequences of Hepatitis B Virus Infection. International Journal of Medical Sciences 2: 36-40.
7. Rapicetta M, Ferrari C, Levrero M, (2002) Viral determinants and host immune responses in the pathogenesis of HBV infection. Journal of Medical Virology 67: 454-457.
8. Rehermann B, Nascimbeni M, (2005) Immunology Of Hepatitis B Virus And Hepatitis C Virus Infection. Nature Reviews Immunology 5: 215-229.
9. Fortuin M, Chotard J, Jack A, Maine N, Mendy M, et al. (1993) Efficacy of hepatitis B vaccine in the Gambian expanded programme on immunisation. Lancet 341: 1129-1131.
10. Sande MABvd, Waight P, Mendy M, Rayco-Solon P, Hutt P, et al. (2006) Long-Term Protection against Carriage of Hepatitis B Virus after Infant Vaccination. The Journal of Infectious Diseases 193: 1528-1535.
11. Whittle H, Maine N, Pilkington J, Mendy M, Fortuin M, et al. (1995) Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. The Lancet 345: 1089-1092.
12. Kirk GD, Lesi OA, Mendy M, Akano AO, Sam O, et al. (2004) The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology 39: 211-219.
13. Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, et al. (2002) Epidemiology, Risk Factors, and Natural History of Hepatocellular Carcinoma. Annals of the New York Academy of Sciences 963: 13-20.
14. Wild CP, Hall AJ, (2000) Primary prevention of hepatocellular carcinoma in developing countries. Mutation Research/Reviews in Mutation Research 462: 381-393.
15. Webster GJM, Reignat S, Brown D, Ogg GS, Jones L, et al. (2004) Longitudinal Analysis of CD8+ T Cells Specific for Structural and Nonstructural Hepatitis B Virus Proteins in Patients with Chronic Hepatitis B: Implications for Immunotherapy. Journal of Virology 78: 5707-5719.
16. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F, (2003) Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: Analysis and review of the literature. Hepatology 37: 1309-1319.
17. Bertoletti A, Ferrari C, (2003) Kinetics of the immune response during HBV and HCV infection. Hepatology 38: 4-13.
18. Bertoletti A, Maini MK, (2000) Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? Current Opinion in Immunology 12: 403-408.
19. Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, et al. (2000) The Role of Virus-specific CD8+ Cells in Liver Damage and Viral Control during Persistent Hepatitis B Virus Infection. Journal of Experimental Medicine 191: 1269-1280.
20. Bertoletti A, Ferrari C, Fiaccadori F, Penna A, Margolskee R, et al. (1991) HLA Class I-Restricted Human Cytotoxic T Cells Recognize Endogenously Synthesized Hepatitis B Virus Nucleocapsid Antigen. Proceedings of the National Academy of Sciences of the United States of America 88: 10445-10449.
21. Rehermann B, Fowler P, Sidney J, Person J, Redeker A, et al. (1995) The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. Journal of Experimental Medicine 181: 1047-1058.
22. Chisari FV, (1997) Cytotoxic T Cells and Viral Hepatitis. Journal of Clinical Investigation 99: 1472-1477.
23. Chisari FV, Ferrari C, (1995) Hepatitis B Virus Immunopathogenesis. Annual Review of Immunology Volume 13: 29-60.
24. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, et al. (1998) Lamivudine Treatment Can Restore T Cell Responsiveness in Chronic Hepatitis B. Journal of Clinical Investigation 102: 968-975.
25. Boni C, Penna A, Bertoletti A, Lamonaca V, Rapti I, et al. (2003) Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. Journal of Hepatology 39: 595-605.
26. Boni C, Penna A, Bertoletti A, Lamonaca V, Rapti I, et al. (2004) Erratum to "Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B": J Hepatol 39 (2003) 595-605. Journal of Hepatology 40: 1053-1054.
27. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, et al. (2001) Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: New perspectives for immune therapy. Hepatology 33: 963-971.
28. Murray JM, Wieland SF, Purcell RH, Chisari FV, (2005) Dynamics of hepatitis B virus clearance in chimpanzees. PNAS 102: 17780-17785.
29. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, et al. (1999) Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection. Science 284: 825-829.
30. Wieland SF, Spangenberg HC, Thimme R, Purcell RH, Chisari FV, (2004) Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. PNAS 101: 2129-2134.
31. Webster GJM, Reignat S, Maini MK, Whalley SA, Ogg GS, et al. (2000) Incubation phase of acute hepatitis B in man: Dynamic of cellular immune mechanisms. Hepatology 32: 1117-1124.
32. Wieland SF, Eustaquio A, Whitten-Bauer C, Boyd B, Chisari FV, (2005) Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. PNAS 102: 9913-9917.
33. Wieland SF, Guidotti LG, Chisari FV, (2000) Intrahepatic Induction of Alpha/Beta Interferon Eliminates Viral RNA-Containing Capsids in Hepatitis B Virus Transgenic Mice. Journal of Virology 74: 4165-4173.
34. Robek MD, Boyd BS, Chisari FV, (2005) Lambda Interferon Inhibits Hepatitis B and C Virus Replication. Journal of Virology 79: 3851-3854.
35. McClary H, Koch R, Chisari FV, Guidotti LG, (2000) Relative Sensitivity of Hepatitis B Virus and Other Hepatotropic Viruses to the Antiviral Effects of Cytokines. Journal of Virology 74: 2255-2264.
36. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA, (1997) DNA VACCINES. Annual Review of Immunology 15: 617-648.
37. Srivastava IK, Liu MA, (2003) Gene Vaccines. Ann Intern Med 138: 550-559.
38. Wang R, Doolan DL, Le TP, Hedstrom RC, Coonan KM, et al. (1998) Induction of Antigen-Specific Cytotoxic T Lymphocytes in Humans by a Malaria DNA Vaccine. Science 282: 476-480.
39. Mancini-Bourgine M, Fontaine H, Brechot C, Pol S, Michel M-L, (2006) Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine 24: 4482-4489.
40. Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Bréchot C, et al. (2004) Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 40: 874-882.
41. Hill AVS, (2006) Pre-erythrocytic malaria vaccines: towards greater efficacy. Nature Reviews Immunology 6: 21-32.
42. McShane H, Hill A, (2005) Prime-boost immunisation strategies for tuberculosis. Microbes and Infection 7: 962-967.
43. Woodland DL, (2004) Jump-starting the immune system: prime-boosting comes of age. Trends in Immunology 25: 98-104.
44. Mayr A, Stickl H, Muller HK, Danner K, Singer H, (1978) The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behaviour in organisms with a debilitated defence mechanism. Zentralbl Bakteriol B 167: 375-390.
45. Gilbert SC, Schneider J, Plebanski M, Hannan CM, Blanchard TJ, et al. (1999) Ty Virus-Like Particles, DNA Vaccines and Modified Vaccinia Virus Ankara; Comparisons and Combinations. Biological Chemistry 380: 299-303.
46. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, et al. (2003) Enhanced Immunogenicity and Protective Efficacy Against Mycobacterium tuberculosis of Bacille Calmette-Guerin Vaccine Using Mucosal Administration and Boosting with a Recombinant Modified Vaccinia Virus Ankara. Journal of Immunology 171: 1602-1609.
47. Hanke T, Samuel RV, Blanchard TJ, Neumann VC, Allen TM, et al. (1999) Effective Induction of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Macaques by Using a Multiepitope Gene and DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccination Regimen. Journal of Virology 73: 7524-7532.
48. McShane H, Brookes R, Gilbert SC, Hill AVS, (2001) Enhanced Immunogenicity of CD4+ T-Cell Responses and Protective Efficacy of a DNA-Modified Vaccinia Virus Ankara Prime-Boost Vaccination Regimen for Murine Tuberculosis. Infection and Immunity 69: 681-686.
49. Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, et al. (1998) Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature Medicine 4: 397-402.
50. Schneider J, Gilbert SC, Hannan CM, Degano P, Prieur E, et al. (1999) Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunological Reviews 170: 29-38.
51. Moorthy V, Pinder M, Reece W, Watkins K, Atabani S, et al. (2003) Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults. Journal of Infectious Diseases 188: 1239-1244.
52. McConkey SJ, Reece WHH, Moorthy VS, Webster D, Dunachie S, et al. (2003) Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nature Medicine 9: 729-735.
53. Pancholi P, Lee D-H, Liu Q, Tackney C, Taylor P, et al. (2001) DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology 33: 448-454.
54. Milich DR, McLachlan A, (1986) The Nucleocapsid of Hepatitis B Virus Is Both a T-Cell-Independent and a T-Cell-Dependent Antigen. Science 234: 1398-1401.
55. Dumpis U, Holmes EC, Mendy M, Hill A, Thursz M, et al. (2001) Transmission of hepatitis B virus infection in Gambian families revealed by phylogenetic analysis. Journal of Hepatology 35: 99-104.
56. Viviani S, Jack A, Hall AJ, Maine N, Mendy M, et al. (1999) Hepatitis B vaccination in infancy in The Gambia: protection: against carriage at 9 years of age. Vaccine 17: 2946-2950.
57. Mendy M, Kaye S, van der Sande M, Rayco-Solon P, Waight P, et al. (2006) Application of real-time PCR to quantify hepatitis B virus DNA in chronic carriers in The Gambia. Virology Journal 3: 23.
58. Cavenaugh JS, Snell P, Jeffries D, Waight PA, McConkey SJ, (2007) A relational database for management of flow cytometry and ELISpot clinical trial data. Cytometry Part B: Clinical Cytometry 72B: 49-62.
59. (2002) BD FastImmune CFC Handbook: Performance Characteristics of Antigen-Specific Cytokine Flow Cytometry (CFC) Assays. BD Biosciences Immunocytometry Systems. 23-6563-00 23-6563-00 pp. 40.
60. Caven TH, (2006) Ige Production Regulation Via Cd23 Stalk Engagement and Cell Cycle Stimulation (doctoral). Richmond Virginia Commonwealth University.
61. Cavenaugh JS, Wang H-K, Hansen C, Smith RS, Herron JN, (2003) How well can a T cell epitope replace its parent carrier protein? A dose response study. Pharmaceutical Research 20: 591-596.
62. Mendy M, McConkey S, Sande van der M, Crozier S, Kaye S, et al. (2008) Changes in viral load and HBsAg and HBeAg status with age in HBV chronic carriers in The Gambia. Virology Journal 5: 49.
63. Nakajima A, Usui M, Huy TT, Hlaing NT, Masaki N, et al. (2005) Full-length sequence of hepatitis B virus belonging to genotype H identified in a Japanese patient with chronic hepatitis. Japanese Journal of Infectious Diseases 58: 244-246.
64. Couillin I, Pol S, Mancini M, Driss F, Bréchot C, et al. (1999) Specific Vaccine Therapy in Chronic Hepatitis B: Induction of T Cell Proliferative Responses Specific for Envelope Antigens. The Journal of Infectious Diseases 180: 15-26.
65. Dahmen A, Herzog-Hauff S, Böcher WO, Galle PR, Löhr HF, (2002) Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. Journal of Medical Virology 66: 452-460.
66. Horiike N, Akbar SMF, Michitaka K, Joukou K, Yamamoto K, et al. (2005) In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. Journal of Clinical Virology 32: 156-161.
67. Pol S, Nalpas B, Driss F, Michel M-L, Tiollais P, et al. (2001) Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. Journal of Hepatology 34: 917-921.
68. Yalcin KM, Danis RM, Degertekin HM, Alp MNP, Tekes SP, et al. (2003) The Lack of Effect of Therapeutic Vaccination With a Pre-S2/S HBV Vaccine in the Immune Tolerant Phase of Chronic HBV Infection. Journal of Clinical Gastroenterology 37: 330-335.
69. Barboza L, Salmen S, Goncalves L, Colmenares M, Peterson D, et al. (2007) Antigen-induced regulatory T cells in HBV chronically infected patients. Virology 368: 41-49.
70. Bejon P, Mwacharo J, Kai O, Mwangi T, Milligan P, et al. (2006) A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya. PLoS Clinical Trials 1: e29.
71. Smith KA, Andjelic S, Popmihajlov Z, Kelly-Rossini L, Sass A, et al. (2007) Immunotherapy with Canarypox Vaccine and Interleukin-2 for HIV-1 Infection: Termination of a Randomized Trial. PLoS Clinical Trials 2: e5.
72. Depla E, Van der Aa A, Livingston BD, Crimi C, Allosery K, et al. (2008) Rational Design of a Multiepitope Vaccine Encoding T-Lymphocyte Epitopes for Treatment of Chronic Hepatitis B Virus Infections. Journal of Virology 82: 435-450.
73. Vandepapelière P, Lau GK, Leroux-Roels G, Horsmans Y, Gane E, et al. (2007) Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: A randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 25: 8585-8597.
74. Jung M-C, Grüner N, Zachoval R, Schraut W, Gerlach T, et al. (2002) Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers. Vaccine 20: 3598-3612.
75. Franzese O, Kennedy PF, Gehring AJ, Gotto J, Williams R, et al. (2005) Modulation of the CD8+-T-Cell Response by CD4+ CD25+ Regulatory T Cells in Patients with Hepatitis B Virus Infection. Journal of Virology 79: 3322-3328.
76. Stoop JN, Molen RG, Baan CC, Laan LW, Kuipers EJ, et al. (2005) Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 41: 771-778.
77. Yoshihiro F, Hirotake T, Satoshi U, Makoto K, Fuminori M, et al. (2005) Depletion of CD25+CD4+T cells (Tregs) enhances the HBV-specific CD8+ T cell response primed by DNA immunization. World Journal of Gastroenterology 11: 3772-3777.
78. Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, et al. (2003) CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 101: 3052-3057.